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Abstract
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare monogenic blistering disorder 
caused by lack of functional type VII collagen, leading to skin fragility and subsequent trauma-
induced separation of the epidermis from the underlying dermis. 46% of RDEB patients harbor at 
least one premature termination codon (PTC) mutation in COL7A1 and previous studies have 
shown that aminoglycosides are able to overcome RDEB PTC mutations by inducing “read-
through” and incorporation of an amino acid at the PTC site. However, aminoglycoside toxicity 
will likely prevent widespread clinical application. Here the FDA-approved drug amlexanox was 
tested for its ability to read-through PTC mutations in RDEB patient derived cells. Eight of 12 
different PTC alleles responded to treatment and produced full length protein, in some cases over 
50% relative to normal controls. Read-through type VII collagen was readily detectable in cell 
culture media and also localized to the dermal-epidermal junction in organotypic skin culture. 
Amlexanox increased COL7A1 transcript and the phosphorylation of UPF-1, an RNA helicase 
associated with nonsense mediated mRNA decay (NMD), suggesting that amlexanox inhibits 
NMD in RDEB patient cells that read-through. This pre-clinical study demonstrates the potential 
of re-purposing amlexanox for treatment of RDEB patients harboring PTC mutation in COL7A1.
*Correspondence: Department of Dermatology & Cutaneous Biology, Thomas Jefferson University, 406 BLSB, Philadelphia, PA 
19107. Andrew.South@Jefferson.edu. 
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INTRODUCTION
Epidermolysis bullosa (EB) is a group of inherited blistering diseases caused by mutations in 
genes encoding proteins critical for skin integrity (Fine et al., 2014). Dystrophic EB is 
caused by mutations in COL7A1 leading to defective type VII collagen, a protein that 
localizes to the basement membrane zone (BMZ) and provides adhesion of the epidermis to 
the dermis through interaction with collagen IV, laminin 332, and collagen I (Brittingham et 
al., 2006; Chen et al., 1999; Villone et al., 2008). Both keratinocytes and fibroblasts 
synthesize and secrete type VII collagen which, after cleavage of the non-collagenous 
carboxy-terminal NC2 domain, assembles in antiparallel tail-to-tail dimers which 
subsequently aggregate to form anchoring fibrils (Bruckner-Tuderman et al., 1995; Chung 
and Uitto, 2010). The proper assembly of anchoring fibrils is required for stable attachment 
between the epidermis and dermis and inability to form anchoring fibrils due to genetic 
mutation in COL7A1 results in skin fragility, trauma-induced blistering followed by chronic 
wounds with poor healing and excessive scarring. The recessive form of dystrophic EB 
(recessive dystrophic EB, RDEB; OMIM #226600) is often a devastating disorder, leading to 
extensive skin blistering, nail dystrophy, alopecia, and mitten deformities of the hands and 
feet. Extracutaneous involvement of esophageal and other mucosal epithelium further 
complicates this disease (Fine et al., 2014; Fine and Mellerio, 2009) and RDEB patients 
suffer from excessive fibrosis at the sites of tissue damage associated with development of 
aggressive and frequently fatal squamous cell carcinomas (Fine et al., 2009; Mittapalli et al., 
2016; Ng et al., 2012). A correlation exists between the amount of type VII collagen present 
at the BMZ and the severity of the disease (McGrath et al., 1993). Premature termination 
codon mutations (PTCs) in COL7A1 are reported in about 46% of RDEB patients (van den 
Akker et al., 2011; Wertheim-Tysarowska et al., 2012), and those individuals harboring two 
PTC mutations (around 10% of cases reported) express very low amounts, if any, of 
truncated type VII collagen and have the most severe subtype of the disease - RDEB-severe 
generalized (Fine et al., 2014).
Significant progress toward development of therapeutic approaches for RDEB has been 
made in recent years (Uitto et al., 2016). Treatment strategies that have shown promising 
pre-clinical data include bone marrow stem cell transplantation (Liao et al., 2015; Tamai et 
al., 2011; Tolar et al., 2009), viral delivery of COL7A1 to correct expression ex-vivo (Chen 
et al., 2002; Jackow et al., 2016; Siprashvili et al., 2010), and protein therapy (Woodley et 
al., 2013). However, those approaches that have translated into the clinic are not without 
complications - in some cases they result in significant mortality (Wagner et al., 2010) or 
involve long and expensive procedures dependent on specialized equipment and 
infrastructure (Siprashvili et al., 2016). More recently, RNA editing approaches have shown 
preclinical promise (Bremer et al., 2016; Goto et al., 2006; Titeux et al., 2010; Turczynski et 
al., 2016), and gene correction by read-through of PTC mutations has been demonstrated in 
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vitro (Cogan et al., 2014). In the latter study, read-through of COL7A1 PTC mutations by 
aminoglycosides demonstrated efficient expression of full length type VII collagen protein 
in patient cells with homozygous PTC mutations. However, systemic long term 
administration of aminoglycosides, such as gentamicin, can be associated with toxicity, 
mainly ototoxity and kidney failure (Tokgoz et al., 2010; Walker and Shah, 1987), which 
will ultimately slow down translation of this drug into clinical practice.
In this study, read-through efficacy of amlexanox, an FDA approved drug previously 
reported to induce read-through in human cells (Gonzalez-Hilarion et al., 2012), was 
evaluated in RDEB patient cells in vitro. Amlexanox was initially approved for the treatment 
of mouth ulcers and is currently in Phase II clinical trials for diabetes mellitus type II 
(www.clinicaltrials.gov). Here pre-clinical evidence is presented supporting amelxanox for 
treatment of RDEB patients harboring PTC mutation in COL7A1.
RESULTS
Amlexanox induces full length type VII collagen synthesis in RDEB fibroblasts and 
keratinocytes with COL7A1 PTC mutation
Previous reports have shown that amlexanox is well tolerated by cultured cells, showing 
little toxicity up to 125 μM concentrations (Gonzalez-Hilarion et al., 2012). In agreement 
with these previous studies, incubation of skin fibroblasts and keratinocytes with amlexanox 
showed little toxicity up to 250 μM, although growth was retarded over 48 hours at higher 
concentrations (Figure S1 and data not shown). Next, RDEB patient cells harboring 
homozygous COL7A1 PTC mutation (p.Q251X) were incubated with a range of amlexanox 
concentrations, and 250 μM was identified as the concentration inducing greatest level of 
full length type VII collagen expression after 48 hours (Figure S2). This dose was used for 
all subsequent experiments. Amlexanox and gentamicin were then assessed for read-through 
in cells derived from 14 RDEB patients harboring 12 different PTC mutations. After 48 
hours of treatment with amlexanox, increased full length type VII collagen (290 kDa) was 
observed by Western blot analysis of total cell lysates from RDEB keratinocytes and 
fibroblasts isolated from eight RDEB patients. In total, four out of 12 PTC mutations did not 
show evidence of read-through (Table 1) either with amlexanox or with gentamicin. In those 
samples with homozygous PTC mutations that responded to treatment, a higher efficacy of 
read-through with amlexanox, compared to gentamicin was observed (Figure 1). In cells 
with compound heterozygous PTC/missense mutations (p.G2073D/p.R578X) a clear 
increase in type VII collagen in total cell lysate was not apparent due to the large amount of 
intracellular protein as result of the presence of the missense mutation (Figure 2a). Overall, 
read-through induced either by amlexanox or by gentamicin was only observed in those 
patient cells which expressed detectable levels of full length type VII collagen, albeit at 
considerably lower levels and presumably as a result of endogenous read-through (Figure 1).
Read-through type VII collagen is stable in cell culture media and localizes to the dermal-
epidermal junction in organotypic culture
To evaluate whether read-through type VII collagen protein is functional, Western blotting of 
proteins isolated from cell culture media was performed and fibrinogen based organotypic 
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skin equivalent cultures using either RDEB or normal cells were prepared. Substitution of a 
pathogenic missense mutation in place of a PTC could affect proper assembly and post-
translational modification of type VII collagen. Collagen triple helix formation is necessary 
to protect type VII collagen monomers from proteolytic degradation after secretion 
(Christiano et al., 1996) and mutations in the non-collagenous domains can affect protein-
protein binding at the BMZ (Brittingham et al., 2006). Western blotting of proteins collected 
from p.G2073D/p.R578X and p.R2610X/p.R2610X keratinocyte culture media after 
treatment with amlexanox and gentamicin showed increased levels of full length type VII 
collagen (Figure 2b), demonstrating stability of read-through protein.
To assess correct dermal-epidermal junction (DEJ) deposition of read-through type VII 
collagen, organotypic cultures were prepared and treated with amlexanox for 2 weeks. Read-
through type VII collagen at the DEJ was then evaluated by immunofluorescence using a 
type VII collagen specific antibody raised against the N-terminal, non-collagenous domain. 
Notable increase in type VII collagen at the DEJ in the RDEB p.Q251X/p.Q251X culture 
was apparent after two weeks of treatment (Figure 2c). An increase in type VII collagen 
synthesis in RDEB p.R578X/p.Q906X organotypic culture was also observed (Figure S3), 
however, a significant amount of intracellular type VII collagen was also detected making it 
difficult to identify a difference at the DEJ. The RDEB culture prepared with G2073D/
R578X cells did not show a clear difference in type VII collagen synthesis between treated 
and non-treated control, which is likely due to the high levels of intracellular protein 
previously detected by Western blotting (Figure 2a) making it difficult to distinguish an 
increase at the DEJ (Figure S3).
Amlexanox increases COL7A1 transcript levels and phosphorylation of the RNA helicase 
UPF1
Amlexanox has previously been shown to inhibit nonsense mediated mRNA decay (NMD) 
in cell based reporter assays (Gonzalez-Hilarion et al., 2012). To investigate whether 
amlexanox increases COL7A1 transcript levels, potentially through inhibition of NMD, 
COL7A1 mRNA was measured using quantitative-PCR (QPCR). Overall base-line levels of 
COL7A1 were not consistently reduced in PTC harboring RDEB keratinocytes while the 
single RDEB fibroblast line tested had around 80% of wild-type levels (Figure 3a). 
Treatment with amlexanox, but not gentamicin, significantly increased mRNA abundance in 
both RDEB keratinocytes and fibroblasts with the exception of p.Q251X/p.Q251X 
keratinocytes. In those cells (3 out of 4) that did show increase in transcript levels after 
amlexanox treatment, COL7A1 expression was around 2-fold or higher compared to 
untreated control cells (Figure 3b). Cycloheximide was used as a positive control for 
increase in transcript levels as previously described (Schneider-Poetsch et al., 2010).
UPF1 is an RNA helicase essential for NMD triggered by premature termination of 
translation upstream of the last exon-exon junction (Isken et al., 2008). It has been shown 
that stabilization of either the non-phosphorylated or the phosphorylated form of UPF1 
inhibits NMD (Kurosaki et al., 2014). As amlexanox increased transcript levels of COL7A1 
in 3 out of 4 RDEB cells, UPF1 levels were evaluated by Western blotting. Read-through 
efficiency correlated with an increase in phosphorylated form of UPF1 (UPF1-P) in all 
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RDEB cells tested Figure 4. No increase in UPF1-P was observed in RDEB cells which did 
not result in read-through with amlexanox treatment (data not shown). Increase in UPF1-P 
was lowest for the single cell population which did read-through but did not exhibit 
increased transcript levels after amlexanox treatment (p.Q251X/p.Q251X keratinocytes).
DISCUSSION
Previous studies have reported that PTC read-through is both codon and context dependent 
(Manuvakhova et al., 2000; McCaughan et al., 1995). Not only the specific sequence of the 
stop codon but also the nucleotide immediately following the stop codon has been shown to 
affect the amount of read-through product. In addition, endogenous (natural) read-through is 
a mechanism that governs protein isoform expression, most notably demonstrated in 
Drosophila (Jungreis et al., 2011), and is both tissue specific and dependent on the 3′ 
nucleotide context (Prieto-Godino et al., 2016). These findings suggest that the termination 
of translation is dependent on factors in addition to the precise trinucleotide sequence of the 
PTC. The data presented here agree with results pertaining to 3′ nucleotide context when 
compared with other read-through studies (Table 1). Among the stop signals tested so far the 
highest efficacy of read-through was observed in the UGA-C sequence and lowest, or no 
efficacy in the UGA-G stop codon combination (Table 1). However, there was inconsistency 
with p.R578X and p.R1933X mutations which did not read-through in two samples 
(RDEB107F and RDEB116K) yet did show read-through in three other samples 
(RDEB13K, RDEB5K, and RDEB115K) even though in each case the stop codon and the 3′ 
nucleotide were identical. In this respect it is of interest to note that those RDEB cells which 
showed read-through with amlexanox also showed read-through with gentamicin and had 
endogenous full length type VII collagen in the untreated control, presumably as result of 
endogenous “leaky” PTC mutation (albeit at much lower levels). This observation suggests 
that read-through is primarily possible in those cells with an endogenous level of read-
through and that this read-through is dependent on as yet unidentified factors. Such factors 
may well be potential disease modifiers in RDEB patients with PTC mutations. Additionally, 
these observations may imply that both gentamicin and amlexanox are acting to enhance 
read-through of PTC mutations in COL7A1 rather than initiating read-through.
When comparing gentamicin with amlexanox, the data presented here demonstrate that 
amlexanox treatment results in greater levels of full length type VII collagen in 8/10 cells 
showing read-through while gentamicin treatment resulted in greater levels in 2/10 cells. We 
attribute this to different mechanisms of action, as amlexanox has been identified as an 
inhibitor of NMD (Gonzalez-Hilarion et al., 2012) while gentamicin, as an aminoglycoside, 
is thought to act on the ribosome (Yoshizawa et al., 1998). Indeed, mRNA data at 24 hours 
after treatment (Figure 3b) identifies increase with amlexanox and not gentamicin, in 
keeping with previous studies showing gentamicin induces transcript increase after 48 hours 
(Baradaran-Heravi et al., 2016), presumably due to feedback as a result of read-through.
Although it has not been demonstrated which amino acid is inserted into the site of the PTC, 
the increase in type VII collagen harvested from amlexanox treated RDEB culture medium 
suggests that read-through type VII collagen is both stable and functional (Figure 2b). This 
conclusion is supported by correct linear deposition of read-through type VII collagen at the 
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DEJ in organotypic culture (Figure 2c). This is not surprising considering that most 
mutations which affect the stability of the protein result in glycine substitutions in the 
collagen triple helix (Christiano et al., 1996; Cserhalmi-Friedman et al., 1997) and the 
mutations tested here did not affect glycine residues (Table 1).
It has been suggested that around 30% of wild type levels of type VII collagen provide 
normal function in a murine model of RDEB (Nystrom et al., 2013) and that type VII 
collagen has a half-life of ~30 days (Kuhl et al., 2016). The study presented here shows that 
the amount of read-through type VII collagen synthesized after a 48 hour treatment with 
amlexanox in vitro varies between 8% and 80% (Figure 1), as compared to healthy control 
cells. These results are promising since even a low level of read-through type VII collagen 
could potentially accumulate with continued treatment, and improve the adhesion of 
epidermis and dermis at the DEJ over time, resulting in improved quality of life for patients.
It should be pointed out that the concentration of amlexanox used in this study is higher than 
that described in the serum of animals receiving 100 mg/kg oral amlexanox, which results in 
>5μM serum concentration (Reilly et al., 2013), and is a lower concentration than 50μM 
which is the lowest dose examined here, and shown to lead to read-through (Figure S2). 
Consequently, further work will be required to ascertain the correct, tolerable dose, needed 
to elicit read-through in RDEB patients.
Other compounds which have shown ability to read-through PTC mutations are in clinical 
use, most notably PTC124 (ataluren) which was approved for treatment of Duchenne 
muscular dystrophy (Finkel, 2010). However, two independent studies have shown that 
PTC124 is not able to induce read-through of PTC mutations in COL7A1, thus suggesting 
PTC124 will not be suitable for RDEB (Cogan et al., 2014; McElroy et al., 2013).
Recent clinical trials have raised hope for RDEB patient treatment but a cure remains elusive 
as a result of complications and limitations within each approach (Uitto et al., 2016). 
Amlexanox is an FDA approved drug for mouth ulcers and currently in phase II clinical trial 
for type II diabetes and for non-fatty liver disease (www.clinicaltrials.gov) where patients 
are treated orally (25 mg/kg) with no adverse side effects reported. Because amlexanox has 
been in clinical use both topically and orally, drug pharmacokinetics and toxicity profiles 
have already been established. That, coupled with the pre-clinical data reported here, 
suggests the possibility of rapid translation into clinical practice in RDEB patients. 
Furthermore, amlexanox has been shown to possess anti-inflammatory properties (Saijo et 
al., 1985) which may have additional benefit for patients in the current context. Indeed, it is 
conceivable that a reduction in inflammatory processes may reduce proteolytic degradation 
within the environment of RDEB wounds leading to improved stability of type VII collagen.
In conclusion, this study demonstrates the feasibility of amlexanox to synthesize full length 
type VII collagen by read-through of PTC mutations in COL7A1 in RDEB patient derived 
cells. The data show that amlexanox could potentially benefit RDEB patients by gradually 
increasing type VII collagen levels at the DEJ while circumventing adverse side effects 
reported for other read-through approaches.
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MATERIALS & METHODS
Cell cultures
Cells were isolated from skin biopsies taken as part of routine surgical or diagnostic 
procedures. Informed written consent was obtained from each patient or in the case of 
under-aged children from their parents or guardian. This study was performed in accordance 
with the Helsinki declaration. All cells were cultured at 37° C at 5% CO2. Human fibroblasts 
were grown in Dulbecco’s modified essential medium (DMEM, Corning cellgro, Mediatech 
Inc, Manassas, VA) supplemented with 10% fetal bovine serum (FBS, PEAK Serum, Cat 
PS-FB1, Colorado, USA). Keratinocytes and fibroblasts were immortalized using the E6 and 
E7 genes of human papillomavirus as described (Halbert et al., 1991). RDEB and normal 
keratinocytes were cultured in DMEM/Ham’s F12 medium (3:1) supplemented with 10% 
FBS, 10 ng/ml of epidermal growth factor, 10−10 M cholera toxin, 0.4 μg/ml of 
hydrocortisone, 5 μg/ml of transferrin, 5 μg/ml of insulin and 5 μg/ml liothyronine. All 
media contained ascorbic acid (150 μM).
Drug treatment and western blot analysis
Fibroblasts or keratinocytes were plated in a 100 mm dish at 8×105 to achieve 70–80% 
confluence the following day, when medium was changed with vehicle or either 250 μM 
amlexanox (Adipogen Life Sciences, San Diego, CA) or 1 mM gentamicin (G1264, Sigma 
Aldrich, St. Louis, MO). Medium was then changed daily containing freshly dissolved drug 
and after 48 hours of treatment cells were lysed with radioimmunoprecipitation assay buffer. 
Lysate was placed in a centrifuge for 5 minutes at 4°C, and the supernatant was mixed with a 
6x Laemmli loading buffer. Before loading onto SDS-PAGE, the samples were boiled for 5 
minutes at 95°C. For type VII collagen detection, 90 μg of protein was loaded on a 6% 
acrylamide gel. Primary antibodies used were: polyclonal rabbit antibody raised against the 
NC1 domain of type VII collagen (kindly provided by Dr. Mei Chen, USC) (dilution 
1:4,000); UPF1 (Cell Signaling, Beverly, MA) (dilution 1:1,000), UPF1-P (Ser1127, EMD 
Millipore, Billerica, MA) (dilution 1:1,000); and β-actin – (Santa Cruz Biotechnology, 
Dallas, TX) (dilution 1:5,000). Resolved proteins were transferred onto nitrocellulose 
membrane with a BioRad Trans-Blot-Turbo (Bio-Rad, Hercules, CA), blocked in PBS-0.1% 
Tween with 5% milk or 5% BSA according to requirements of the primary antibody, and 
incubated overnight with the primary antibody. After incubation with IgG-HRP conjugated 
secondary antibody (Santa Cruz Biotechnology), membrane was incubated with Pierce ECL 
Western blotting substrate (Fisher Scientific, Waltham, MA) and exposed to CL-XPosure X-
ray film (Fisher Scientific, Waltham, MA).
Protein Quantification
Total cell lysates were quantified with Pierce bicinchoninic assay Protein Assay kit (Fisher 
Scientific, Waltham, MA) and 90 μg of protein were loaded onto SDS-PAGE gel. Western 
blot signal was quantified with Image J. Type VII collagen was quantified relative to β-actin 
and to non-treated control. UPF1-P was quantified relative to total UPF1 protein amount and 
non-treated control.
Atanasova et al. Page 7
J Invest Dermatol. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Metabolic activity assay
Cells were seeded in 96-well plate (1×104 cells/well) and incubated with given doses of the 
respective drug for 48 hours as described. After 48 hours the medium was changed with 
DMEM 10% FBS + WST-1 substrate (Roche Diagnostics, Manheim, Germany) (final 
WST-1 concentration 10%). After 30 minutes incubation at 37°C the absorbance was 
measured using Flex Station 3 plate reader (Molecular Devices, Sunnyvale, CA) at 450 nm.
Live/Dead Cell Assay
Cells were seeded in a black 96 well plate (3×104 cells/well) and treated over 48 hours with 
amlexanox. After 48 hours a working solution of 6 μM calcein AM and 6 μM EtD-III was 
added to the cells according to manufacturer’s instructions (EarlyTox Live/Dead Assay; 
Molecular Devices, Sunnyvale, CA). After 40 minutes of incubation at room temperature in 
the dark, fluorescence was measured with Flex Station 3 plate reader (Molecular Devices, 
Sunnyvale, CA) at two wavelengths – excitation at 495 nm and emission at 530 nm; 
excitation at 530 nm and emission at 645 nm.
qRT-PCR
Keratinocytes and fibroblasts were plated in six well plates for 90% confluence the next day. 
Cells were treated with the respective drug for 24 hours and total RNA was isolated using 
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
RNA extractions were quantified using a NanoDrop Spectrophotometer (Fisher Scientific, 
Waltham, MA) and 1.5 μg RNA was used for cDNA synthesis using SuperScript III First-
Strand Synthesis System (Invitrogen, Life Technologies, Carlsbad, CA). For detection of 
COL7A1 expression, the following primers were used: forward primer 
GGCTGCAATTCTCCATGTGG, and reverse CTGTGAGGCAACTCGCTTCA. For ACTB 
amplification, the following primers were used: forward CATGTACGTTGCTATCCAGGC, 
and reverse CTCCTTAATGTCACGCACGAT. For qPCR, SYBR Select Master mix (Life 
technologies, Carlsbad, CA) was used and cDNA samples were diluted 1:25 to serve as 
template. Experiments were performed in triplicate.
Organotypic skin equivalents
Bovine fibrinogen (90% clottable, MP Biomedicals, Santa Ana, CA) was dissolved in 1.1% 
NaCl at 37°C for 4 hours and then filtered with a 0.45 μm nylon membrane filter. Fibroblasts 
were collected with the use of trypsin and a centrifuge, and re-suspended in media to a final 
concentration 2×106 cells per ml. 150 μl of this cell suspension was mixed with 1 ml of 
thrombin (3 IU - Sigma Aldrich, St. Louis, MO), and this cell/thrombin mix was added to 
fibrinogen at a ratio of 1:1. The mixture was quickly but gently distributed 1 ml/well into a 
24-well plate and incubated at 37°C. After 20 minutes medium supplemented with ascorbic 
acid and aprotinin (Sigma, St. Louis, MO; final concentration 10 μg/ml) was added. The 
matrices were left to mature for 5–7 days while medium was changed every other day. 
Keratinocytes were plated on top at 2×106 per well and on the next day the culture was 
raised to the air-liquid interface on a metal grid and treatment with amlexanox was started; 
medium was changed every other day with fresh drug, ascorbic acid and aprotinin. Cultures 
were collected at one or two weeks of treatment and frozen with OCT in liquid nitrogen 
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cooled isopentane. 8 μM sections were cut using a cryostat (AVANTIK QS11) and 
immunostained with the polyclonal type VII collagen antibody at a dilution of 1:800. Nuclei 
were counterstained with DAPI (Invitrogen, Carlsbad, CA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Amlexanox induces full length type VII collagen synthesis in RDEB patient derived cells. 
Keratinocytes (a and b) and fibroblasts (c) isolated from different RDEB patients were 
treated with 250 μM amlexanox (A) or gentamicin 1 mM (G). Expression of type VII 
collagen after treatment was compared to normal human keratinocytes or fibroblasts (NHK 
or NHF) using Western blotting. For optimization of detection, the amount of protein loaded 
from RDEB keratinocytes (not fibroblasts) was twice the amount of protein loaded from 
control cells. Levels of type VII collagen expression were quantified in image J relative to β-
actin and non-treated controls (NT). Graph shows protein levels as a percentage of normal 
cells.
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Figure 2. 
Read-through type VII collagen is stable and locates to the dermal-epidermal junction. 
RDEB cells harboring G2073D/R578X mutations and R2610X/R2610X mutations were 
assessed for levels of intracellular type VII collagen (a) and levels of secreted type VII 
collagen (b) using Western blotting. Treatment with amlexanox and gentamicin stabilizes 
secreted levels of the protein. For optimization of detection, the amount of protein loaded 
from RDEB cells was twice the amount of protein loaded from control cells. (c) Treatment 
of organotypic skin cultures with amlexanox for two weeks increases type VII collagen 
deposition at the dermal-epidermal junction (DEJ). Organotypic skin cultures were prepared 
using RDEB cells or wild type cells, and synthesis of type VII collagen at the DEJ was 
evaluated using immunofluorescence staining. The magnification bar = 400 μM.
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Figure 3. 
Amlexanox increases transcript levels of COL7A1 in 3 out of 4 RDEB patient cells. (a) 
Evaluation of baseline levels of COL7A1 transcript compared to normal keratinocytes and 
fibroblasts shows relatively similar levels of expression. (b) Treatment with amlexanox (250 
μM) increases COL7A1 transcript in all but one population of RDEB cells. Gentamicin (1 
mM).
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Figure 4. 
Read-through synthesis of type VII collagen correlates with increase in UPF1 
phosphorylation state. RDEB or wild type cells were cultured in 100 mm dishes and treated 
with either amlexanox or gentamicin for 48 hours. Levels of UPF1-P were quantified in 
image J relative to total levels of UPF1 and non-treated controls.
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